AbbVie Inc (4AB.DU)
Dusseldorf - Dusseldorf Delayed price. Currency in EUR
Add to watchlist
At close: 07:30PM CEST
| Previous close | 154.92 |
| Open | 154.46 |
| Bid | 157.32 x N/A |
| Ask | 157.82 x N/A |
| Day's range | 154.30 - 156.86 |
| 52-week range | 118.90 - 168.00 |
| Volume | |
| Avg. volume | 2 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 25 Jul 2024 - 29 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireAbbVie Recommends Shareholders Reject Tutanota's "Mini-Tender" Offer
AbbVie (NYSE: ABBV) has been notified that Tutanota LLC (Tutanota) has commenced an unsolicited "mini-tender" offer, dated May 28, 2024, to purchase up to 250,000 shares of AbbVie common stock at $165.00 per share in cash (Offer Price).
ZacksPharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
An FDA panel endorses Eli Lilly's (LLY) Alzheimer's disease drug, donanemab. Pfizer's (PFE) DMD study on investigational gene therapy fails.
ZacksAbbVie (ABBV) Buys Global Rights to Novel IBD Candidate
AbbVie (ABBV) signs an exclusive global licensing deal with the Chinese company FutureGen to develop FG-M701, a next-generation TL1A antibody, for IBD indications.
© 2024 Yahoo. All rights reserved.